Ceftaroline Fosamil Injection (Teflaro)

Elliott, William T.; Chan, James
March 2011
Internal Medicine Alert;3/29/2011, Vol. 33 Issue 6, p46
The article offers information on the drug Teflaro (ceftaroline fosamil), a parenteral cephalosporin from Forest Pharmaceuticals Inc.


Related Articles

  • Ceftaroline Fosamil--A New Broad-Spectrum Cephalosporin with Significant Activity against Methicillin-Resistant Staphylococci. Guay, David R. P. // Clinical Medicine Reviews in Therapeutics;2011, Vol. 3, p27 

    Ceftaroline fosamil (PPI-0903, TAK-599, Teflaro®, Forest Pharmaceuticals) is the prodrug for ceftaroline (T-91825), a broadspectrum parenteral (IM/IV) cephalosporin with potent in vitro and in vivo activity against methicillin- and vancomycin-resistant staphylococci as well as other common...

  • TEFLARO.  // Monthly Prescribing Reference;Jan2011, Vol. 27 Issue 1, pA.10 

    The article provides brief information on Teflaro, an antibiotic drug from Forest Pharmaceuticals Inc. , which is used for susceptible bacterial community-acquired pneumonia.

  • Many common infections respond to cefprozil.  // Modern Medicine;Jul95, Vol. 63 Issue 7, p56 

    Presents an abstract of the article titled `Cefprozil, a new cephalosporin: Its use in various clinical trials,' by R.B. Gainer II originally published in the March 1995 issue of `South Medical Journal.'

  • Bug beater. Portyansky, Elena // Drug Topics;1/19/98, Vol. 142 Issue 2, p28 

    Presents information on the drug `Omnicef (cefdinir) which is the tenth third-generation cephalosporin in the United States. Indications carried by the extended-spectrum, semisynthetic oral cephalosporin which is manufactured by Warner-Lambert; Details on the availability of Omnicef.

  • Oral, once-daily, broad-spectrum cephalosporin antibiotic.  // Modern Medicine;Mar96, Vol. 64 Issue 3, p32 

    Reports on the approval of Ceftibuten cephalosphorin in the United States for treating mild-to-moderate infections. Conditions allowed for using the drug; Effectivity against strains of Hemophilus influenzae and Moraxella catarrhalis; Dosage; Contraindications.

  • Cefepime is effective against several kinds of infection. Cerrato, Paul L. // RN;Jun96, Vol. 59 Issue 6, p70 

    Focuses on the cephalosporin antibiotic called cefepime for the treatment of urinary tract infections UTIs), skin infections and pneumonia.

  • A new cephalosporin to battle respiratory infections. Cerrato, Paul L. // RN;Jul96, Vol. 59 Issue 7, p70 

    Reports on the US Food and Drug Administration's (FDA) approval of the third-generation oral cephalosporin ceftibuten for patients with chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis. Recommended dosage; Most common adverse reactions.

  • European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe (1997–2009). Versporten, Ann; Coenen, Samuel; Adriaenssens, Niels; Muller, Arno; Minalu, Girma; Faes, Christel; Vankerckhoven, Vanessa; Aerts, Marc; Hens, Niel; Molenberghs, Geert; Goossens, Herman // Journal of Antimicrobial Chemotherapy (JAC);Feb2012, Vol. 67 Issue 2, p518 

    A correction to the article "European Surveillance of Antimicrobial Consumption (ESAC): Outpatient Cephalosporin Use in Europe," published in the 2011 issue, is presented.

  • Forest receives untitled letter for Celexa. Dickinson, James G. // Medical Marketing & Media;Nov2002, Vol. 37 Issue 11, p36 

    Reports that promotional materials for Forest Pharmaceutical's Celexa were deemed misleading and lacking fair balance, according to the Drug Marketing, Advertising and Communications division of the U.S. Food and Drug Administration.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics